Body Composition

Tirzepatide

Tirzepatide (Dual GIP/GLP-1 Receptor Agonist)

First-in-class dual incretin studied for metabolic and weight outcomes

Research Status: FDA-approved (T2D & obesity); extensive Phase III data LY3298176 Mounjaro Zepbound
Mechanism of Action

How it works

Tirzepatide activates both the GIP and GLP-1 receptors. This dual incretin action enhances glucose-dependent insulin secretion, slows gastric emptying, and acts on appetite-regulating pathways in the brain - a combination researchers associate with its metabolic effects.

Areas of Research

What the research explores

In published research, Tirzepatide has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.

  • Studied extensively for body weight reduction
  • Improves glycemic control markers in research
  • Acts on appetite and satiety signaling
  • Dual receptor mechanism investigated vs. single-agonist agents
  • Researched for cardiometabolic and lipid markers
Research Highlight

The SURMOUNT clinical program reported substantial mean body-weight reductions at the highest doses studied, among the largest seen with an incretin therapy to date.

Safety Profile

Adverse events & gaps

Well-characterized in large trials. Most commonly reported effects are gastrointestinal (nausea, reduced appetite), typically dose-related.



Stay Informed on
Peptide Research

Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.

No spam. Unsubscribe at any time.